Novacyt S.A.
NCYT:LN
Latest Coverage
Overview
Company Profile
Novacyt Group, an international specialist in cancer and infectious diseases, has diversified sales from diagnostic products used in LBC, oncology, microbiology, haematology and serology testing. We support a large global customer base which includes hospitals to large corporates
We support a large global customer base which includes hospitals to large corporates. Our proprietary technology platform NOVAPREP® is a unique next generation liquid based cytology solution focused on cancer management.
Classification
Financials
News & Media
Latest Coverage
Corporate
Board of Directors
Graham Mullis
Chief Executive Officer
Appointed CEO of Novacyt in 2014 Over 30 years in healthcare; pharmaceuticals & medical device markets Internationally experienced leader with multi-disciplinary background Led multiple successful exits; Biocompatibles Eyecare, ClearLab, VisionTec and Optivue C-level executive with FTSE 250 (Biocompatibles International) and NASDAQ (1-800 CONTACTS)
Anthony Dyer
Chief Financial Officer
Joined Group in 2010 17 years in healthcare; pharmaceuticals & medical devices Growth business and M&A experience, including RiboTargets / British Biotech and BioFocus / Galapagos FCCA qualified 20 years; commercial and audit background
James Wakefield
Non-Exec Director & Chairman of the Board
James is an experienced private equity investor having spent almost 30 years in the industry. His vast experience ranges from chairing a number of successful Board teams, investment committees and being involved with originating/executing new transactions, portfolio management and fundraising. James has been Chairman or Non-Executive Director of over 30 companies of varying sizes/stages of development across a wide range of sectors.
Dr Andrew Heath
Non-exec Director
Dr Heath is a healthcare and biopharmaceutical executive with in-depth knowledge of US and UK capital markets with international experience in marketing, sales, R&D and business development. He is currently Deputy Chairman and SID of Oxford BioMedica plc, a director of IHT LLC and Anew Inc. From 1999 to 2008 he was CEO of Protherics plc, taking the company from 30 to 350 staff and managing its eventual acquisition by BTG Plc for £220 million. A former director of The Bioindustry Association, Dr Heath earlier served as Vice President of Marketing and Sales, for Astra Inc. in the US after a career in clinical and academic medicine at Vanderbilt University.
Ed Snape
Non-exec Director
Ed has over 35 years of experience in founding, investing in, and guiding the development of many public and private healthcare and specialty materials companies. Ed holds several patents in the advanced materials field where he has pioneered various technological innovations and authored numerous technical papers. He has been a recipient of several awards in the material sciences industry, including the AB Campbell Award and the Hunt Silver Medal and received BS and PhD degrees in metallurgy from Leeds University, England.
Jean-Pierre Crinelli
Non-exec Director
One of the founders of Novacyt in July 2006. 30 years in the car and electrical components industry (various functions/M&A/business restructuring). Of which 10 years Outside France: Singapore, North America, Belgium and Italy.
Juliet Thompson
Non-exec Director
Non-executive Chairman of Premier Vet Group, listed on London Stock Exchange Non-executive Vice Chairman of Nexstim, a listed Finnish medical technology company A 20+ years strong track record advising listed healthcare companies in UK and Europe as an investment banker Managing Director Nomura Code Chartered Accountant and substantial experienced in equity fundraisings and M&A